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ABSTRACT 
The objective of this study was to evaluate the effect of pantoprazole and pregabalin on experimental esophagitis in albino rats. The 
groups of rats fasted for 24 hours and were subjected to pylorus and forestomach ligation. Rats of different groups received normal 
saline (3 ml/kg, po; sham control), pantoprazole (30 mg/kg, po), pregabalin (30 mg/kg, po) and their combinations along with a 
parallel toxic control group. Animals were sacrificed after 8 h and evaluated for the gastric pH, total acidity, free acidity and 
esophagitis index. The morphological changes were scrutinized by digital microscopy. The beneficial effect of pantoprazole and 
pregabalin against GERD could be attributed to the anti-secretory action of pantoprazole and reduction in the tracheal lower 
esophageal sphincter release rate by pregabalin. Combination therapy of gamma-aminobutyric acid derivative promotes proton pump 
inhibitor based healing of reflux esophagitis in animal model. 
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INTRODUCTION  
The occurrence of gastro esophageal reflux disease 
(GERD) in India ranges from 8 to 20% as stated by a 
recently conducted study.
1
 Esophagitis is the 
inflammation of the lining of the esophagus, the tube 
that carries food from throat to the stomach. If left 
untreated, then this condition can become very 
uncomfortable causing troublesome of swallowing, 
ulcers, scarring of esophagus, esophageal cancer etc. 
When acid from the stomach leaks up into the gullet 
(esophagus), the condition is known as reflux. 
Therefore, gastro esophageal reflux is the return of 
stomach's contents back into the esophagus. GERD is a 
digestive disorder that affects the lower esophageal 
sphincter (LES), the ring of muscle between esophagus 
and stomach. In normal digestion, the LES opens to 
allow food to pass into the stomach and closes to prevent 
food and acidic stomach juices from flowing back into 
the esophagus. Gastro esophageal reflux occurs when 
the LES is weak or relaxes inappropriately. Symptoms 
of GERD consist of difficulty in swallowing 
(dysphagia), pain during swallowing (odynophagia), 
acid reflux, heart burn, nausea & vomiting, abdominal 
pain, sore throat, hoarse voice, cough and sometimes 
muscle ache or fever.
2 
Endoscopically GERD broadly 
classified into two groups; Erosive esophagitis or 
Barrett’s esophagus (having esophageal mucosal 
damage) and non-erosive reflux disease, NERD (no 
mucosal damage).
3,4
 The pathophysiology of GERD is 
multifactorial, involving transient lower esophageal 
sphincter relaxation (TLESR), reduced LES pressure, 
poor esophageal clearance, impaired esophageal 
mucosal defense, visceral hypersensitivity, hiatal hernia 
and delayed gastric emptying. The enhanced acid 
secretion and reflux mechanism suggests playing a key 
role in the elementary pathogenesis of GERD. 
5.6
 
Irregularities in the gastro-esophageal junction, the 
stomach, the esophagus and the nervous system may all 
contribute to this disease state.
7
 Mechanism of gastro-
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esophageal reflux befallen by three different 
mechanisms: transient complete relaxation of the lower 
esophageal sphincter, a transient increase in intra-
abdominal pressure, or spontaneous free reflux 
associated with a low resting pressure of the lower 
esophageal sphincter.
8
  For all immune-compromised 
patients, the most frequently identified esophageal 
pathogen is Helicobacter pylori.
9
  
Both genetic and environmental factors appear to 
influence the presence of GERD. Several studies have 
shown that obesity, weight gain, pregnancy, frequent 
vomiting and increasing body mass index (BMI) are 
associated with GERD. 
10,11
 Research also indicates that 
some risk factors as smoking, excess alcohol 
consumption, irritable bowel syndrome and a family 
history of upper GI disease are responsible for GERD. 
Consuming certain foods and drinks in large quantities 
regularly such as tomato-based ones, citrus fruits, 
chocolates, garlics, onions, spicy foods and caffeine’s 
can cause GERD. Factors also contribute to GERD are 
Hiatal hernia, Zollinger Ellison syndrome, NASIDS, 
anti-cholinergics, antidepressants. 
12
 GERD is a chronic 
disorder that often requires long-term maintenance 
therapy. Proton pump inhibitors (PPIs) are the most 
effective therapy.
13,14
 Pantoprazole is a PPI used in the 
treatment of dyspepsia, peptic ulcer disease, gastro-
esophageal reflux disease and Zollinger–Ellison 
syndrome. 
15,16 
Pantoprazole suppress the final step in gastric acid 
production by forming a covalent bond to two sites of 
the (H
+
-K
+
) - ATPase enzyme system. This phenomenon 
occurs at the secretory surface of the gastric parietal cell.  
The maintenance therapy by PPIs alone is not very 
effective due to weak inhibitory activity in early phase 
and less effectiveness of the therapy within the initial 
hours of dosing. 
17
 Pregabalin is a derivative of gamma-
amino butyric acid (GABA) and is a potent ligand for 
the alpha-2-delta subunit of voltage-gated calcium 
channels in the central nervous system.
18
 A recent study 
has revealed that pregabalin reduces the tracheal lower 
esophageal sphincter release rate (TLESR) and reflux 
episode by increasing esophageal sphincter basal 
pressure and accelerating gastric emptying. 
19,20
 
The present study was put forward to evaluate the effect 
of monotherapy and combination therapy of pregabalin 
and pantoprazole on experimentally induced esophageal 
lesions in rat model.
21
 
MATERIALS AND METHODS 
Drugs and Chemicals 
Pantoprazole was received as a gift sample from Alkem 
Laboratories Ltd Baddi, Himachal Pradesh 173205, and 
Pregabalin was procured from the local market. All other 
chemicals used were of analytical grade. 
Animals 
Wistar strain albino rats (80–120 g) were obtained from 
Breeding Centre BHU. Rats were kept in polypropylene 
cages under standard condition of temperature (37±1
0
C) 
and 40-45% relative humidity with 12 h light: 12 h dark 
cycle. Rats were provided with commercial pellet diet 
and water ad libitum. The experimental protocol was 
approved by Institutional Animal Ethical Committee 
(IAEC) of UIP, Allahabad (Ref. number 
UIP/IAEC/2015/10). 
Induction of Esophagitis 
Animals were randomized and divided into five groups 
of six animals in each, fasted for 24 h, received, sham 
control (normal saline, 3 ml/kg, po), toxic control 
(pylorus and forestomach ligated; normal saline, 3 
ml/kg, po), pantoprazole (pylorus and forestomach 
ligated; 30 mg/kg, po), pregabalin (pylorus and 
forestomach ligated; 30 mg/kg, po), and their 
combination (pylorus and forestomach ligated; 30 
mg/kg+30 mg/kg, po). After 1 h, coeliotomy was 
accomplished and esophagitis was induced by ligating 
the forestomach and pylorus with 2-0 silk suture under 
pentobarbitone anesthesia (50 mg/kg, ip) (Figure1).
22 
 
 
Figure 1: Demonstration of forestomach and pylorus ligation. 
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After 8 h animals were sacrificed by cervical dislocation 
and the abdomen was opened with a median incision 
and the esophagus & the stomach were removed. The 
tissue was washed with distill water and examined for 
lesion. The severity of the erosions was scored using 
Table 1 and the esophagitis index was calculated by 
dividing the total score by ten. 
23 
 
Table 1: Scoring table of esophagitis index 
 Erosion(mm) 1 or less 1-2 2-3 >3 
Score 1 2 3 4 
 
The pH is measured by using a pH meter (Paras). The 
volume of gastric juices was dignified as described 
consequently under “gastric secretion in pylorus ligated 
rats”. 24 
Estimation of free radical generation 
Esophageal tissue was minced well, homogenized in 
ice-cold 0.01 M Tris–HCl buffer, pH 7.3 and exposed to 
the evaluations of thiobarbituric acid reactive substances 
(TBARS), tissue glutathione (GSH), catalase and 
superoxide dismutase (SOD). 
25,26,27,28 
Histological Evaluation 
Digital Microscopy of esophageal tissue has been done 
for the study of the tissues before and after the therapy. 
The tissues for histological study were embedded in 
paraffin wax and sectioned on a rotary microtome at 
6µm thickness followed by staining of the tissue with 
hematoxyline. The stained sections were observed under 
a Dewinter microscope and digital photomicrographs 
were taken. 
Statistical Analysis 
All the data were offered as mean ± SD and analyzed by 
one way ANOVA followed by Bonferroni test for the 
possible significance identification between the various 
groups.  Statistical analysis was carried out using Graph 
pad software (3.2). 
RESULTS 
Treatment with combination therapy of pantoprazole 
and pregablin significantly controlled the lesion 
formation in esophagus. The combination therapy of 
pantoprazole and pregablin produced 73.42% inhibition 
of esophagitis index respectively. The amalgamation of 
pantoprazole and pregabalin, inhibited the esophagitis 
index, decreased the volume of gastric juices, total 
acidity and increased the gastric pH to a judgmental 
level (Table 2), suggesting the possible synergistic 
effect. Earlier studies have explained the role of free 
radicals in pathogenesis of the reflux esophagitis in 
experimental animals.
29
 Reflux esophagitis has been 
testified to increase Malondialdehyde (MDA), a stable 
product of lipid peroxidation and a sensitive marker of 
membrane damage. 
30,31
 The oxidative stress leads to 
deprivation of cellular membrane which produces MDA. 
It is a reactive species that reacts to form a color 
complex with thiobarbituric acid and we recorded a 
momentous upsurge in MDA augmentation in toxic 
control group. 
32,33
 Associated administration of the 
pantoprazole and pregablin as a monotherapy and 
combination therapy critically inhibited the lipid 
peroxidation expressed by decreased TBARS levels, that 
is, 2.87±0.01, 1.89±0.04, and 1.07±0.01 nmol of 
MDA/mg of protein, respectively (Table 3). 
 
Table 2 Effect of pantoprazole and pregabalin on gastric content, pH, free acidity, total acidity and esophagitis index in 
albino rats. 
Groups Treatment(p.o.) pH Volume of 
gastric 
juices(ml/100g) 
Esophagitis 
index 
Total acidity 
(mEq/l) 
Free Acidity 
(mEq/l) 
 
Group- I Sham Control 
(3.0 ml/kg) 
3.52±0.21*** 1.53±0.23*** 0.65±0.34*** 28.22±1.06*** 26.73±1.45*** 
Group- II Toxic Control 
(Normal Saline 
3 ml/kg) 
2.78±0.32 5.43±0.19 1.66±0.12 80.48±3.16 56.33±2.41 
Group-III Pantoprazole 
(30 mg/kg) 
3.29±0.11 1.51±0.33* 
 
0.50±0.11*** 
 
42.78±1.05*** 
 
32.67±1.13*** 
 
Group- IV Pregabalin (30 
mg/kg) 
3.42±0.26*** 1.89±0.24*** 
 
0.91±0.26* 
 
47.26±1.29*** 
 
37.15±1.33*** 
 
Group- V Pantoprazole 
+Pregabalin 
(30mg/kg and 
30 mg/kg) 
3.30±0.12** 1.81±0.32** 
 
0.72±0.18*** 
 
 
45.26±0.65*** 
 
33.74±1.57*** 
 
Each group contains six animals. Data is represented as Mean±SD. Statistical significance compared to toxic control using one-way 
ANOVA followed by Bonferroni test where *p<0.05, **p<0.01, ***p<0.001 were considered statistically significant.  
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Table 3 Effect of pantoprazole and pregabalin therapy on TBARS, protein carbonyl, GSH, Catalase and SOD in albino 
rats subjected to forestomach and pylorus ligation. 
Groups TBARS 
(Nm of MDA 
/mg of protein) 
Protein carbonyl 
(nmoles/ml) 
 
GSH*10
4  
(mg %) 
SOD 
(unit of SOD/mg  
of protein) 
Catalase 
(nM of H2O2/min/ 
mg of protein 
Group-I 0.72±0.01*** 62.66±3.02*** 2.16±0.11*** 7.68±2.83 20.11±2.53 
Group-II 6.72±0.07 128.10±22.28 0.97±0.10 3.56±1.22 6.21±0.83 
Group-III 2.87±0.01*** 85.48±9.11* 1.62±0.03*** 3.03±1.23*** 15.21±4.03*** 
Group-IV 1.89±0.04*** 81.98±10.23** 2.06±0.09 6.31±2.31 21.22±2.38*** 
Group-V 1.07±0.01*** 74.73±12.83** 2.08±0.24*** 6.05±2.77*** 22.53±2.12*** 
Each group contains six animals. Data is represented as Mean±SD. Statistical significance compared to toxic control using one-way 
ANOVA followed by Bonferroni test. 
DISCUSSION 
A momentous increase in protein carbonyl content was 
determined in toxic control as analogous of sham control 
and combination therapy afforded considerable 
inhibition of oxidative stress. Similarly the GSH level in 
toxic group (0.97±0.10 mg %) reduced as compared to 
control group (2.16±0.11 mg %), after combination 
therapy is restored (2.06±0.09 mg %). The glutathione 
(GSH) is a universal tripeptide, which is the most 
abundant low molecular weight thiol in almost all cells 
and is tangled in an extensive range of enzymatic 
reaction. A major role of GSH is to serve as a reductant 
in oxidation reduction processes, a function causing the 
formation of glutathione disulfide (GSSG). Free radical 
destruction leads to consumption of GSH in the first few 
hours of oxidative stress, leading reduced GSH level, a 
marker of short term oxidative stress, and treatment with 
pantoprazole and pregabalin has significantly facilitated 
to re-establish the same. 
34,35
 
In the same way experimental esophagitis diminished 
the level of SOD 3.56±1.22, in comparison of normal 
group 7.68±2.83, combination therapy enhanced it 
further 6.05±2.77 unit of SOD/mg of protein. SOD is a 
free radical scavenging enzyme it counterpoises 
superoxide-free radicals produced during the metabolism 
of drug, hence its concentration in the tissue reduces 
with increase in the time. SOD functions as an 
antioxidant and diminishes oxidative stress in the 
experimental rats. SOD scavenges the H2O2 to form 
water and molecular oxygen.
36
 The procedure includes 
the formation of hydroxyl and molecular oxygen free 
radical as the intermediate products. 
37 
The SOD in 
conjugation with catalase organizes the foremost 
protection against free radicals. 
Correspondingly, in toxic group catalase protein 
condensed 6.21±0.83 from 20.11±2.53 (sham control) 
and in union therapy is re-established to 22.53±2.12 nM 
of H2O2/min/mg of protein. Catalase is a hemeprotein 
which catalyses the reduction of hydrogen peroxide and 
shield the membrane from extremely reactive hydroxyl 
radical. 
38
 The catalase protein production increased by 
the treatment of this fusion therapy. 
It is remarkable that pregabalin shows better healing 
effect alone as well as in combination with pantoprazole 
without any untoward effect, which is not the case for 
present therapeutic options for GERD. Pregabalin 
illustrates ameliorative effects on esophageal tissues. 
 
 
Figure 2: Morphological changes of esophagus in different groups as observed through Microscopy:  (A)Sham 
Control, (B) Toxic Control (3.0 ml/kg normal saline), (C) Pantoprazole(30 mg/kg), (D) Pregabalin (30mg/kg) and (E) 
Pantoprazole (30mg/kg)+ Pregabalin (30mg/kg). 
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The ultra-structural changes including dilated 
intracellular spaces and mucosa degeneration is a well-
studied phenomenon and same was observed when 
studied microscopically. Marked ultra-structural damage 
with mucus degeneration was observed in toxic group 
comparison to sham control; treatment with 
amalgamation therapy demonstrated marked 
microscopic protection. The figure depicts that the 
combination therapy of pantoprazole and pregabalin 
significantly reduced the ulceration as compared to the 
individual therapy (Fig. 2).  
This study revealed that the unification therapy of 
pantoprazole and pregabalin elucidates reasonable 
protection against the surgical esophagitis. Ligating the 
forestomach and pylorus developed reflux esophagitis in 
all the rats blotted by macroscopically visible necrosis 
and substantial ulceration in the esophagus. Dealing 
with pantoprazole and pregabalin suggestively inhibited 
the ulcer formation in esophagus. Pantoprazole is a 
proton pump inhibitor showing H+K+ ATPase and 
carbonic anhydrase inhibitory activity. 
39
 Pantoprazole is 
an engrained drug used for the treatment of peptic ulcer, 
which prevents the secretion from the gastric cells and 
helps in providing relief in GERD. 
40
 Pantoprazole 
covalently binds to cysteine residue of proton pump and 
obstructs the secretion of gastric acid. 
41
 It inhibits the 
secretion from gastric cells and helps in effecting 
consolation in reflux disease and mucosal curing in 
gastric ulcer and GERD. The beneficial effects of 
pregabalin perceived in the current study could be 
accredited to its capability to condense TLESR by 
increasing esophageal sphincter basal pressure and 
accelerated gastric emptying. 
42
 The combination of 
pantoprazole and pregabalin subdued the esophagitis 
index, diminished the volume of gastric juices, and 
condensed the pH to a major level, signifying the 
thinkable synergistic effect. Thus, the effect against 
GERD could be congregately attributed to the 
antisecretory action of pantoprazole and reduction of 
TLESR by pregabalin. 
CONCLUSIONS 
This preclinical study concludes that the fusion therapy 
of pantoprazole and pregabalin is showing synergistic 
effect in the treatment of GERD. Pregabalin alone as 
well as in combination with pantoprazole can heal the 
esophagitis symptoms. We can find more analytical data 
by doing clinical studies on the same combination. 
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